In December 1965, Eastern Airlines Flight 853 collided mid-air with a descending Boeing 707 near the CARMEL VOR in New York. The impact tore away critical tail surfaces and severed control systems, ...

Lee Zeldin, the E.P.A. administrator, revived a plan created during the first Trump administration to end the testing of chemicals on mammals. By Lisa Friedman The Environmental Protection Agency will ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Vor Biopharma experienced a remarkable morning on December 9, 2025, as shares of the biotech company surged more than 40% in premarket trading. The dramatic rally came after JPMorgan analysts ...

Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Advanced in organs on chips, digital twins, and AI are ushering in a new era of research and drug development. Earlier this week, the UK’s science minister announced an ambitious plan: to phase out ...

As we get into another winter holiday season, COVID is still part of our lives. And although it's hard to predict exactly what this year's cold, flu and coronavirus season will look like, experts want ...

Hours prior to his meeting with Chinese President Xi Jinping, U.S. President Donald Trump posted on social media, “Because of other countries testing programs, I have instructed the Department of War ...

VOR Biopharma's valuation surged after in-licensing telitacicept and securing PIPE financing, but capital structure uncertainty persists. Telitacicept's positive phase 3 data in Sjögren's disease ...

Vor Bio grants CEO Jean-Paul Kress an option to purchase 83.3 million shares at $0.89, vesting over four years. Vor Bio, a biotechnology company specializing in autoimmune disease treatments, ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 bispecific from Harbour BioMed to develop against autoimmune diseases.